- Home
- VTYX vs NVCT Comparison
VTYX vs NVCT Comparison
Compare VTYX & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- NVCT
- Stock Information
- Founded
- VTYX 2018
- NVCT 2020
- Country
- VTYX United States
- NVCT United States
- Employees
- VTYX N/A
- NVCT N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- VTYX Health Care
- NVCT Health Care
- Exchange
- VTYX Nasdaq
- NVCT Nasdaq
- Market Cap
- VTYX 154.9M
- NVCT 167.0M
- IPO Year
- VTYX 2021
- NVCT 2022
- Fundamental
- Price
- VTYX $3.65
- NVCT $6.03
- Analyst Decision
- VTYX Buy
- NVCT Strong Buy
- Analyst Count
- VTYX 3
- NVCT 3
- Target Price
- VTYX $10.00
- NVCT $15.33
- AVG Volume (30 Days)
- VTYX 1.5M
- NVCT 92.1K
- Earning Date
- VTYX 11-06-2025
- NVCT 11-04-2025
- Dividend Yield
- VTYX N/A
- NVCT N/A
- EPS Growth
- VTYX N/A
- NVCT N/A
- EPS
- VTYX N/A
- NVCT N/A
- Revenue
- VTYX N/A
- NVCT N/A
- Revenue This Year
- VTYX N/A
- NVCT N/A
- Revenue Next Year
- VTYX N/A
- NVCT N/A
- P/E Ratio
- VTYX N/A
- NVCT N/A
- Revenue Growth
- VTYX N/A
- NVCT N/A
- 52 Week Low
- VTYX $0.78
- NVCT $4.44
- 52 Week High
- VTYX $4.05
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- VTYX 62.22
- NVCT 43.87
- Support Level
- VTYX $3.48
- NVCT $5.85
- Resistance Level
- VTYX $4.04
- NVCT $6.21
- Average True Range (ATR)
- VTYX 0.30
- NVCT 0.24
- MACD
- VTYX 0.04
- NVCT 0.03
- Stochastic Oscillator
- VTYX 72.93
- NVCT 60.27
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.